Mount Sinai and Stony Brook Announce Affiliation
August 11, 2016 – Stony Brook Medicine and the Mount Sinai Health System today announced that they are entering into an affiliation agreement that includes collaboration on research, academic programs and clinical care initiatives, effective immediately. The institutions launched the partnership to heighten …
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
June 22, 2016 – Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn …
Mount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disease
May 3, 2016 – Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has signed an investigator initiated clinical trial …
Takeda Launches Multi-Year Research Partnership with Leading Inflammatory Bowel Disease Institutions
March 31, 2016 – Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), today announced a multi-year research partnership with two world leading academic centers with a proven long-term commitment to inflammatory bowel disease (IBD) research and care. The partnership, with the University of Chicago and the …
Dual Therapeutics Announces Oncology Strategic Collaboration with Bristol-Myers Squibb
January 8, 2016 – Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases. Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer promoting pathways, …
“Dark Matter” in Cancer Genome Prompts Immune Response
December 7, 2015 – Researchers at the Icahn School of Medicine at Mount Sinai have discovered a group of non-coding RNA molecules in cancer cells that sets off an immune response because they appear to have features similar to those of pathogens. As …
Mount Sinai Innovation Partners Launches New Web Resources for Faculty
Mount Sinai Innovation Partners, MSIP, is a business unit of the health system that facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships. MSIP recently launched new resources on their website, www.ip.mountsinai.org, for faculty, staff and …
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
November 10, 2015 – Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel disease (IBD), including the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, …
‘JEDI’ Technology Awakens New Understanding of How Immune System Works
November 4, 2015 – When it comes to fending off disease and helping prevent people from falling ill, the body’s immune system — armed with T-cells that help eliminate cancer cells, virus-infected cells and more — is second to none. But exactly how …
Mount Sinai Innovation Awards
On Monday, October 26, 2015, Mount Sinai Innovation Partners sponsored the first ever Mount Sinai Innovation Awards Ceremony, celebrating five new honors that recognize significant contributions in biomedical education and industry. Through the dedication of presenters, participants, attendees, and our generous sponsors, SINAInnovations …